Cargando…

Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6‐independent manner

Palbociclib, a CDK4/6 inhibitor, has recently been approved for hormone receptor‐positive breast cancer patients. The effects of palbociclib as a treatment for other malignancies, including hepatocellular carcinoma (HCC), are of great clinical interest and are under active investigation. Here, we re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsieh, Feng‐Shu, Chen, Yao‐Li, Hung, Man‐Hsin, Chu, Pei‐Yi, Tsai, Ming‐Hsien, Chen, Li‐Ju, Hsiao, Yung‐Jen, Shih, Chih‐Ting, Chang, Mao‐Ju, Chao, Tzu‐I, Shiau, Chung‐Wai, Chen, Kuen‐Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537702/ https://www.ncbi.nlm.nih.gov/pubmed/28453226 http://dx.doi.org/10.1002/1878-0261.12072

Ejemplares similares

Canagliflozin inhibits growth of hepatocellular carcinoma via blocking glucose-influx-induced β-catenin activation
por: Hung, Man-Hsin, et al.
Publicado: (2019)

Novel therapeutic strategy for melanoma based on albendazole and the CDK4/6 inhibitor palbociclib
por: Zhu, Lin, et al.
Publicado: (2022)

Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy
por: van Aken, Evert S. M., et al.
Publicado: (2021)

CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation
por: Hou, Yi-Bo, et al.
Publicado: (2019)

Severe Cellular Immunodeficiency Triggered by the CDK4/6 Inhibitor Palbociclib
por: Guillaume, Zoé, et al.
Publicado: (2020)

Protein tyrosine phosphatase 1B targets PITX1/p120RasGAP thus showing therapeutic potential in colorectal carcinoma
por: Teng, Hao-Wei, et al.
Publicado: (2016)

Corrigendum: Protein tyrosine phosphatase 1B targets PITX1/p120RasGAP thus showing therapeutic potential in colorectal carcinoma
por: Teng, Hao-Wei, et al.
Publicado: (2017)

SH2 domain-containing phosphatase 1 regulates pyruvate kinase M2 in hepatocellular carcinoma
por: Tai, Wei-Tien, et al.
Publicado: (2016)

Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
por: Pandey, Kamal, et al.
Publicado: (2020)

Analysis of the selection of CDK4/6 inhibitors based on experience using palbociclib
por: Kikuchi, Mariko, et al.
Publicado: (2019)

Baicalein protects against oxLDL-caused oxidative stress and inflammation by modulation of AMPK- alpha
por: Tsai, Kun-Ling, et al.
Publicado: (2016)

P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib
por: Li, Paiyun, et al.
Publicado: (2019)

Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma
por: Hu, Ming-Hung, et al.
Publicado: (2017)

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
por: Braal, C. Louwrens, et al.
Publicado: (2020)

Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity
por: Pogacar, Ziva, et al.
Publicado: (2022)

Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
por: Lu, Janice
Publicado: (2015)

SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A
por: Hung, Man-Hsin, et al.
Publicado: (2015)

CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
por: Raspé, Eric, et al.
Publicado: (2017)

Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells
por: Cretella, Daniele, et al.
Publicado: (2019)

Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity
por: Jin, Dan, et al.
Publicado: (2019)

Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy
por: Huang, Tzu-Ting, et al.
Publicado: (2017)

AMPK promotes Arf6 activation in a kinase-independent manner upon glucose starvation
por: Chen, Kuan-Jung, et al.
Publicado: (2022)

Two Novel Palbociclib-Resorcinol and Palbociclib-Orcinol Cocrystals with Enhanced Solubility and Dissolution Rate
por: Duan, Chenxin, et al.
Publicado: (2021)

Analysis of the CDK4/6 Cell Cycle Pathway in Leiomyosarcomas as a Potential Target for Inhibition by Palbociclib
por: Böhm, Michael J., et al.
Publicado: (2019)

Glucose Metabolic Reprogramming of ER(+) Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib
por: Lorito, Nicla, et al.
Publicado: (2020)

Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict’s value
por: Chow, Louis W C, et al.
Publicado: (2017)

Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDKN2A
por: Martin-Broto, Javier, et al.
Publicado: (2023)

Metformin Resensitizes Sorafenib-Resistant HCC Cells Through AMPK-Dependent Autophagy Activation
por: Lai, Hong-Yue, et al.
Publicado: (2021)

CDK4/6 Inhibitor Palbociclib Amplifies the Radiosensitivity to Nasopharyngeal Carcinoma Cells via Mediating Apoptosis and Suppressing DNA Damage Repair
por: Xie, Xianhe, et al.
Publicado: (2019)

Overexpression of miRNA-3613-3p Enhances the Sensitivity of Triple Negative Breast Cancer to CDK4/6 Inhibitor Palbociclib
por: Yu, Yuanhang, et al.
Publicado: (2020)

Nifuroxazide boosts the anticancer efficacy of palbociclib-induced senescence by dual inhibition of STAT3 and CDK2 in triple-negative breast cancer
por: Wang, Xianzhe, et al.
Publicado: (2023)

Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib
por: Miettinen, Teemu P, et al.
Publicado: (2018)

Palbociclib-mediated cell cycle arrest can occur in the absence of the CDK inhibitors p21 and p27
por: Pennycook, Betheney R., et al.
Publicado: (2021)

The Acquired Vulnerability Caused by CDK4/6 Inhibition Promotes Drug Synergism Between Oxaliplatin and Palbociclib in Cholangiocarcinoma
por: Suppramote, Orawan, et al.
Publicado: (2022)

Cigarette smoke-induced LKB1/AMPK pathway deficiency reduces EGFR TKI sensitivity in NSCLC
por: Cheng, Fang-Ju, et al.
Publicado: (2020)

Trait representation of embodied cognition in dancers pivoting on the extended mirror neuron system: a resting-state fMRI study
por: Yang, Ching-Ju, et al.
Publicado: (2023)

Farnesoid X Receptor Overexpression Decreases the Migration, Invasion and Angiogenesis of Human Bladder Cancers via AMPK Activation and Cholesterol Biosynthesis Inhibition
por: Lai, Chien-Rui, et al.
Publicado: (2022)

Interleukin-4 Promotes Myogenesis and Boosts Myocyte Insulin Efficacy
por: Chang, Yih-Hsin, et al.
Publicado: (2019)

In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts
por: Passeri, Thibault, et al.
Publicado: (2022)

The CDK4/6 Inhibitor Palbociclib Inhibits Estrogen-Positive and Triple Negative Breast Cancer Bone Metastasis In Vivo
por: Saleh, Lubaid, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ofq088s5oce6kdmgm80ht0m22q